Mekinist (Trametinib)

Fact about Mekinist

  • Brand Name- Mekinist
  • Innovator Brand Name- Mekinist
  • API- Trametinib
  • Packaging- 30 Tablets
  • Strength- 2 mg
  • Manufacturer Name- Novartis Ltd
Get Price

Description

What is Trametinib and what it is used for:

Trametinib (Mekinist) is a kinase inhibitor class drug used in the treatment of patients suffering from unresectable or Metastatic Melanoma with V600K or BRAF V600E mutations.

Trametinib, when combined with dabrafenib, is used in the treatment of a patient suffering from Melanoma with BRAF V600E or V600K mutations.

Dosage: Trametinib is available in tablet form of strength 0.5mg and 2mg. It should be taken orally at about the same time each day, either with or without food. Trametinib tablets should be gulped whole with the water. The tablet should not be unwrapped, broken, or chewed.

Treatment Reactions:

  • When trametinib 2 mg is used as a single agent the common side effects include diarrhea, lymphoedema, and Rash.
  • Trametinib side effects when it is combined with the dabrafenib drug include nausea, diarrhea, vomiting, peripheral edema, pyrexia, chills, and hypertension.
  • Some other side effects when this drug is used for the treatment of other diseases such as Melanoma and non-small cell lung cancer are cough, Rash, decreased appetite, chills, hemorrhage, dry skin, pyrexia, nausea, diarrhea, vomiting, fatigue, headache, rash, and arthralgia.

Warning and Precautions:

  • When trametinib 2 mg is combined with dabrafenib it can cause Cutaneous and Non-cutaneous and New Primary Malignancies.
  • There may be signs and symptoms of major hemorrhage.
  • Colitis and Gastrointestinal Perforation is very common in the patient receiving mekinist 2 mg.
  • Pulmonary embolism and Venous Thromboembolism occur in patients receiving this treatment.
  • Using mekinist 2 mg during pregnancy may cause potential damage to the foetus.
  • Cardiomyopathy may be a common problem for two to three months of treatment.
  • Retinal Vein Occlusion may be reported.
  • If any problem of interstitial lung disease occurs discontinue treatment with mekinist permanently.
  • Constantly monitor for hyperglycemia.
  • Serious febrile reactions can occur when used with dabrafenib.
  • Monitor for any skin toxicity, and discontinue mekinist for serious reactions.

Supplied/Storage and Handling

Care should be exercised in the handling of Trametinib. Trametinib tablets should not be opened or crushed. Store permitted between 20°C to 25°C (68°F to 77°F).

Commonly Asked questions

WHEN TRAMETINIB WAS APPROVED AS A SINGLE AGENT?

TRAMETINIB holded the approval in May of 2013, as a single-agent by the FDA (Food and Drug Administration) for treating patients with the V600E mutated metastatic melanoma.

How can I get MEKINIST:

MEKINIST is a prescription drug and is not approved for marketing in India.

The Indian Pharma (IP) is a consulting pharmaceutical company which assists Patients in accessing medicines in India. The Indian Pharma facilitates such access only against valid prescriptions in conformity with all local laws and regulations.

Patients/ Clinicians / Researchers can contact IP at +91-120-4080562 or write to at – info@theindianpharma.com

Can I get MEKINIST even if I am not based in India?

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country

The Indian Pharma (IP) can help patients in accessing/importing MEKINIST, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

How is MEKINIST used?

MEKINIST should be administered under the guidance of specialist doctor having experience in managing cancer treatments.
The recommended dosage regimens of MEKINIST are 2 mg orally once daily as a single agent or in combination with dabrafenib 150 mg orally twice daily. Take MEKINIST at least 1 hour before or at least 2 hours after a meal.
If the patient develops certain serious side effects then doctor may interrupt or stop treatment, or reduce the dose. See the summary of product characteristics on company official website for more information

How do I contact The Indian Pharma?

You can use different channel to contact The Indian Pharma (IP)
Tele & Mobile: You can reach us on +91 8826990915 or +91-120-4080562 on any working days.
Email: We can also address your enquiries if sent directly to info@theindianpharma.com. We will respond within 24 hours after receiving your mail. Please mention detailed inquiry, your contact number with ISD code while sending your mail. We will respond within 1 working days after receiving your query form.

What information do you need to help patient in assisting documentation for MEKINIST import for personal use?

We will require the following documents to help in documentation for Named-Patient import

  • Doctor’s Prescription – We would require a prescription from a Registered Medical Practitioner Stating Product name, dosage, duration of treatment and diagnosis

  • Patient’s Medical history – We would require all test reports and Medical reports of the patient for last 3 months.

  • Patient’s Identity card – We will require a scan copy of Patient’s identity card and proof of residence to initiate documentation process. You can use a copy of Passport, Driving License, Employee ID card or any Photo ID document as your Identity card.

Disclaimer- All Trademark and Brand that appear on the website belong to their respective owners and The Indian Pharma does not lay any claim on them we only provide Information. Trametinib is a pharmaceutical drug that legally requires a medical prescription to be dispensed.

Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.